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risk of stroke, the most likely explanation for which is embolisation of thrombus to the systemic circulation during removal of the thrombectomy catheter.
Is selective use of thrombectomy in selected patients reasonable? None of the subgroup analyses in TOTAL, including patient age, presence of diabetes, coronary fl ow grade, smoking status, location of infarction, or type of anticoagulation used during the invasive procedure provide support for this idea. Thrombectomy might help improved lesion overview, direct stenting, stent sizing, and apposition, and could serve as a bailout treatment in no-refl ow scenarios, but we must weigh up the potential benefi ts in individual cases against the overall absence of positive eff ects and the small associated risk of stroke.
In the European Union and elsewhere, introduction of new medical devices, such as thrombectomy catheters, is not as tightly regulated as is the introduction of new pharmaceutical therapies. Although this situation might off er advantages to patients in terms of timely access to important device innovations, it leads to poor clinical assessment and an increased risk of unexpected complications and absence of benefi t. The problem is not confi ned to invasive cardiology-almost 8% of primary hip replacement prostheses implanted in the UK do not have evidence for clinical eff ectiveness and longevity.
12 The 1-year results from TASTE and TOTAL should serve as a caveat against the introduction of new medical techniques and devices into routine clinical use until clinical endpoint data from adequately powered trials or data from high-quality health registries are available. 
Genetics and phenotypes in infl ammatory bowel disease
Infl ammatory bowel diseases, encompassing Crohn's disease and ulcerative colitis, have long been recognised as very heterogeneous dis eases at the clinical level.
Farmer and colleagues 1 were among the fi rst to report that location of disease was a major driver for disease presentation, complications, and rates of surgery. More recently, the Montreal and Paris classifi cations (ie, modifi ed Montreal classifi cation for use in paediatric infl ammatory bowel disease) have tried to standardise clinical phenotypes further, acknowledging that age at diagnosis, and location and extent of disease in Crohn's disease and ulcerative colitis, and disease behaviour in Crohn's disease, are the main factors aff ecting disease course and prognosis. 2, 3 For example, younger age at diagnosis is generally associated with more extensive and aggressive disease in both Crohn's disease and ulcerative colitis; ileal (L1) and ileocolonic (L3) Crohn's disease are more frequently associated with stenosing and fi stulising complications and need for surgery than is colonic Crohn's disease (L2); and in ulcerative colitis, extensive disease (E3) usually has higher therapeutic requirements, risk of colorectal cancer, and rates of hospital admission and surgery than does non-extensive disease (E1 and E2). 2 The phenotypic concordance reported in familial cases of infl ammatory bowel disease and in monozygotic twins with infl ammatory bowel disease has long served as an argument that shared environmental and genetic factors shape disease phenotype. 4, 5 Beginning with the early linkage studies, and continuing through identifi cation of the NOD2 gene until the most recent era of genome-wide association studies, progress has been enormous, culminating in the identifi cation of 163 independent loci associated with infl ammatory bowel disease. 6 We have learned that Crohn's disease and ulcerative colitis share several disease susceptibility loci, many of which are implicated in other immune-mediated diseases. 6 Furthermore, the discoveries of genes related to T-helper-17 cell diff erentiation and function, and genes infl uencing innate immunity and microbial immune response, have brought major insights into disease pathogenesis, pointing to altered bacterial handling as a key factor in disease pathogenesis. 7 Clearly, the next logical step would be to dissect genotype-phenotype relations, in the hope of identifying infl ammatory bowel disease subtypes that could be translated into the clinic. In The Lancet, Isabelle Cleynen and colleagues 8 report the largest genotype-phenotype study ever undertaken in infl ammatory bowel disease. The investigators are to be congratulated for the enormous international collaborative eff ort, with detailed phenotypic data gathered for many patients with infl ammatory bowel disease, and for their meticulous and well designed statistical methodology. Overall, 29 838 patients with infl ammatory bowel disease were genotyped with the Immunochip array (designed to capture almost 200 diff erent loci associated with common autoimmune diseases), and variants in the MHC were imputed. That important phenotypic conclusions would be drawn from such a well powered study might be expected; unfortunately, this was not the case.
The major fi ndings were, fi rst, that the previously proposed relation between NOD2 and stenosing disease is not a true one; rather, it is driven by NOD2 association with young age at diagnosis and ileal location; and second, that colonic disease location (L2) for Crohn's disease was better predicted by the HLA susceptibility alleles of ulcerative colitis than by the susceptibility alleles of Crohn's disease. To investigate this fi nding further, the researchers resorted to predictive models of disease location and showed that colonic Crohn's disease is genetically intermediate between ileal Crohn's disease and ulcerative colitis. Cleynen and colleagues 8 conclude that colonic Crohn's disease is genetically distinct from ileal Crohn's disease, and propose a new nomenclature for infl ammatory bowel disease (however, L3 disease-the most common disease location-is inexplicably left out).
Only three main loci (NOD2, MHC, and 3p21/MST1) achieved genome-wide signifi cance for association with clinical phenotypes in Cleynen and colleagues study, 8 but when combined in a predictive model with Coronary artery disease is the largest contributor to cardiovascular diseases and the number one cause of death in western countries. Percutaneous coronary intervention (PCI) has become the most commonly done interventional procedure in medicine, and coronary artery bypass grafting (CABG) has become one of the most commonly done forms of major surgery. 1,2 The number of CABG operations done each year has remained constant, whereas the number of PCI procedures has increased and now accounts for an increasing proportion of revascularisation procedures. 3 Patients with complex lesions often still require CABG because of the signifi cantly higher adverse event rates with PCI that are largely attributable to increases in rates of repeat revascularisation. 4 Incomplete revascularisation is one of the reasons for adverse outcomes after PCI, and clinical-demographic factors, these loci were unable to explain disease variance. Next to NOD2, age at diagnosis and smoking were the main drivers for disease location in adult Crohn's disease, whereas, for ulcerative colitis, age at diagnosis was the most important determinant of disease extent, albeit of modest eff ect.
The feeble tone of our criticism merely refl ects our disappointment that, in essence, Cleynen and colleagues' strongly powered study, 8 which focused mainly on genetic factors, provides only limited new phenotypic insights. No genetic loci associated with perianal disease, upper gastrointestinal disease, or extra-intestinal manifest ations were identifi ed. No genetic predictors of disease progression in Crohn's disease, or of disease extent or proximal extension in ulcerative colitis, could be detected (fi gure).
So how should we interpret the results? As pointed out by Cleynen and colleagues, the analysis was restricted to the known variants determining disease risk, and therefore it is possible that important loci infl uencing disease course remain to be identifi ed. For example, rare variants with larger eff ects could have a profound eff ect in disease subphenotypes. Novel approaches such as whole-genome and exome sequencing will perhaps bring additional insight. Fundamentally, it is clear that gene-environment connections need to be more systematically interrogated. Epigenetic factors, mediating the interactions between genetics and complex environmental exposures such as the microbiome, could potentially provide new clues to disease pathogenesis in the years to come. 9, 10 Importantly, many of the classic clinical and epidemiological fi ndingssuch as the relation with smoking, the macroscopic distribution of disease, and the mesenteric fat hypertrophy in Crohn's disease-remain to be explained. 11 Cleynen and colleagues' study highlights the urgent need for innovative thinking and the development of a new research roadmap that systematically integrates genetic with non-genetic factors.
